<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04260321</url>
  </required_header>
  <id_info>
    <org_study_id>2363-2</org_study_id>
    <nct_id>NCT04260321</nct_id>
  </id_info>
  <brief_title>The AID Study 2: Artificial Intelligence for Colorectal Adenoma Detection 2</brief_title>
  <official_title>The AID Study 2: Artificial Intelligence for Colorectal Adenoma Detection 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Colonoscopy is clinically used as the gold standard for detection of colon cancer (CRC) and
      removal of adenomatous polyps. Despite the success of colonoscopy in reducing cancer-related
      deaths, there exists a disappointing level of adenomas missed at colonoscopy. &quot;Back-to-back&quot;
      colonoscopies have indicated significant miss rates of 27% for small adenomas (&lt; 5 mm) and 6%
      for adenomas of more than 10 mm in diameter. Studies performing both CT colonography and
      colonoscopy estimate that the colonoscopy miss rate for polyps over 10 mm in size may be as
      high as 12%. The clinical importance of missed lesions should be emphasized because these
      lesions may ultimately progress to CRC.

      Limitations in human visual perception and other human biases such as fatigue, distraction,
      level of alertness during examination increases such recognition errors and way of mitigating
      them may be the key to improve polyp detection and further reduction in mortality from CRC.
      In the past years, a number of CAD systems for detection of polyps from endoscopy images have
      been described. However, the benefits of traditional CAD technologies in colonoscopy appear
      to be contradictory, therefore they should be improved to be ultimately considered useful.
      Recent advances in artificial intelligence (AI), deep learning (DL), and computer vision have
      shown potential to assist polyp detection during colonoscopy.

      Young endoscopists (each having performed &lt;2000 screening colonoscopies and ADR &lt; 25%) will
      perform the endoscopic procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority of AI-aided colonoscopy in terms of ADR</measure>
    <time_frame>5 Months</time_frame>
    <description>The proportion of participants with at least one adenoma (per-patient analysis).</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>AI</arm_group_label>
    <description>Artificial intelligence colonoscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>White light colonoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AI</intervention_name>
    <description>Artificial intelligence colonoscopy</description>
    <arm_group_label>AI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Based on the observed prevalence of adenomas (35%) among patients undergoing colonoscopies
        at our center within the last 12 months, a sample size of 322 subjects per arm could allow
        for a 90% power to show the non-inferiority (primary end-point) of the AI-aided arm by
        excluding that the one-side 95% CI will exclude a difference of 10% in favour of the
        standard group. Such sample size will also have a 80% power to detect as statistical
        significant (Î±=0.05; two-sided test) a 10% absolute increase in the detection rate of
        adenomas in the AI-aided arm (secondary end-point).

        Performing a sub-stratification according to operator experience, we will planning to
        enroll the 322 subjects per arm performed by experts and 322 subjects per arm performed by
        average operator.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All 40-80 years-old subjects undergoing a colonoscopy

        Exclusion Criteria:

          -  subjects with personal history of CRC, or IBD.

          -  patients with inadequate bowel preparation (defined as Boston Bowel Preparation Scale
             &gt; 2 in any colonic segment).

          -  patients with previous colonic resection.

          -  patients on antithrombotic therapy, precluding polyp resection.

          -  patients who were not able or refused to give informed written consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alessandro Repici, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Humanitas Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alessandrto Repici, MD</last_name>
    <phone>0039-02-82247493</phone>
    <email>alessandro.repici@hunimed.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione Poliambulanza</name>
      <address>
        <city>Brescia</city>
        <state>Italia</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristiano Spada</last_name>
      <phone>0039-030/3515372</phone>
      <email>cristiano.spada@poliambulanza.it</email>
    </contact>
    <investigator>
      <last_name>Cristiano Spada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endoscopy Unit, Humanitas Research Hospital</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Repici, MD</last_name>
      <phone>+39282247493</phone>
      <email>alessandro.repici@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Alessandro Repici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Fugazza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessia Galtieri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gaia Pellegatta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milena Di Leo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Valduce</name>
      <address>
        <city>Como</city>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franco Radaelli, MD</last_name>
      <email>francoradaelli01@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Franco Radaelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive Endoscopy Unit, Nuovo Regina Margherita Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cesare Hassan, MD</last_name>
      <email>cesareh@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Cesare Hassan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ente Ospedaliero Cantonale, Ospedale Italiano</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea De Gottardi, MD</last_name>
      <email>Andrea.DeGottardi@eoc.ch</email>
    </contact>
    <contact_backup>
      <last_name>Gianluca Lollo, MD</last_name>
      <email>Gianluca.Lollo@eoc.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea De Gottardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gianluca Lollo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Artificial Intelligence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

